Cargando…

Tacrolimus Monotherapy is Safe in Immunologically Low-Risk Kidney Transplant Recipients: A Randomized-Controlled Pilot Study

In this randomized-controlled pilot study, the feasibility and safety of tacrolimus monotherapy in immunologically low-risk kidney transplant recipients was evaluated [NTR4824, www.trialregister.nl]. Low immunological risk was defined as maximal 3 HLA mismatches and the absence of panel reactive ant...

Descripción completa

Detalles Bibliográficos
Autores principales:	de Weerd, Annelies E., Fatly, Zainab Al, Boer-Verschragen, Marieken, Kal-van Gestel, Judith A., Roelen, Dave L., Dieterich, Marjolein, Betjes, Michiel G. H.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Health Archive
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9637544/ https://www.ncbi.nlm.nih.gov/pubmed/36353052 http://dx.doi.org/10.3389/ti.2022.10839

Ejemplares similares

The Burden of Gastrointestinal Complaints in Kidney Transplant Recipients Using Tacrolimus With and Without Mycophenolate Mofetil: A Randomized Controlled Study
por: Fatly, Zainab Al, et al.
Publicado: (2022)

Is simplification of immunosuppressive medication a way to promote medication adherence of kidney transplant recipients? Findings from a randomized controlled trial
por: van Zanten, Regina, et al.
Publicado: (2021)

Increasing Kidney-Exchange Options Within the Existing Living Donor Pool With CIAT: A Pilot Implementation Study
por: de Klerk, Marry, et al.
Publicado: (2023)

Causes of Kidney Graft Failure in a Cohort of Recipients With a Very Long-Time Follow-Up After Transplantation
por: Betjes, Michiel G. H., et al.
Publicado: (2022)

Lowering maintenance immune suppression in elderly kidney transplant recipients; connecting the immunological and clinical dots
por: Betjes, Michiel G. H., et al.
Publicado: (2023)

COVID-19 Vaccination Response in Kidney Transplant Recipients With and Without Mycophenolate Mofetil: Follow-up of a Randomized Controlled Trial
por: Al Fatly, Zainab, et al.
Publicado: (2022)

Pretransplant Donor-Specific Anti-HLA Antibodies and the Risk for Rejection-Related Graft Failure of Kidney Allografts
por: Betjes, Michiel G. H., et al.
Publicado: (2020)

Prolonged-Release Once-Daily Formulation of Tacrolimus Versus Standard-of-Care Tacrolimus in de novo Kidney Transplant Patients Across Europe
por: Budde, Klemens, et al.
Publicado: (2022)

Tacrolimus Exposure Before and After a Switch From Twice-Daily Immediate-Release to Once-Daily Prolonged Release Tacrolimus: The ENVARSWITCH Study
por: Monchaud, Caroline, et al.
Publicado: (2023)

The FCGR3A 158 V/V-genotype is associated with decreased survival of renal allografts with chronic active antibody-mediated rejection
por: Litjens, Nicolle, et al.
Publicado: (2021)

Increased Tacrolimus Exposure in Kidney Transplant Recipients With COVID-19: Inflammation-Driven Downregulation of Metabolism as a Potential Mechanism
por: Klomp, Sylvia D., et al.
Publicado: (2022)

The detrimental effect of donor-specific antibodies is irrespective of its level in highly-immunized living donor kidney transplant recipients: A case-control series
por: Tramper, T., et al.
Publicado: (2023)

The Tacrolimus Concentration/Dose Ratio Does Not Predict Early Complications After Kidney Transplantation
por: von Samson-Himmelstjerna, Friedrich Alexander, et al.
Publicado: (2023)

How Heidelberger and Avery sweetened immunology
por: Van Epps, Heather L.
Publicado: (2005)

Understanding the Immunology of Normothermic Machine Perfusion
por: Clatworthy, Menna Ruth, et al.
Publicado: (2023)

SARS-CoV-2 Infection Can Lead to an Increase in Tacrolimus Levels in Renal Transplant Patients: A Cohort Study
por: Chalklin, Christopher G., et al.
Publicado: (2022)

Complement-Binding Donor-Specific Anti-HLA Antibodies: Biomarker for Immunologic Risk Stratification in Pediatric Kidney Transplantation Recipients
por: Sigurjonsdottir, Vaka K., et al.
Publicado: (2022)

Interferon-Gamma DNA Methylation Is Affected by Mycophenolic Acid but Not by Tacrolimus after T-Cell Activation
por: Peters, Fleur S., et al.
Publicado: (2017)

Chronic Pancreas Allograft Rejection Followed by Successful HLA-Incompatible Islet Alloautotransplantation: A Novel Strategy?
por: Veltkamp, Denise M. J., et al.
Publicado: (2023)

Uremia-Associated Immunological Aging and Severity of COVID-19 Infection
por: Betjes, Michiel G. H.
Publicado: (2021)

Occurrence of intraocular hemorrhages under monotherapy or combination therapy of antiplatelets and anticoagulants using the Japanese Adverse Drug Event Report database
por: Tanaka, Junko, et al.
Publicado: (2023)

Renal Function, Adherence and Quality of Life Improvement After Conversion From Immediate to Prolonged-Release Tacrolimus in Liver Transplantation: Prospective Ten-Year Follow-Up Study
por: Toti, Luca, et al.
Publicado: (2022)

Analysis of NFATc1 amplification in T cells for pharmacodynamic monitoring of tacrolimus in kidney transplant recipients
por: Kannegieter, Nynke M., et al.
Publicado: (2018)

Favorable Effects of Tacrolimus Monotherapy on Myasthenia Gravis Patients
por: Fan, Zhirong, et al.
Publicado: (2020)

I Doubt It Is Safe: A Meta-analysis of Self-reported Intolerance of Uncertainty and Threat Extinction Training
por: Morriss, Jayne, et al.
Publicado: (2021)

Tacrolimus intra-patient variability is not associated with chronic active antibody mediated rejection
por: Sablik, Kasia A., et al.
Publicado: (2018)

Efficacy and safety of tacrolimus monotherapy versus tacrolimus-corticosteroid combination therapy for idiopathic membranous nephropathy: A meta-analysis
por: Gong, Lifeng, et al.
Publicado: (2021)

The Effect of Tacrolimus and Mycophenolic Acid on CD14+ Monocyte Activation and Function
por: Kannegieter, Nynke M., et al.
Publicado: (2017)

Immunological role and prognostic value of SPARCL1 in pan-cancer analysis
por: He, Kangwei, et al.
Publicado: (2022)

Late antibody-mediated rejection after ABO-incompatible kidney transplantation during Gram-negative sepsis
por: de Weerd, Annelies, et al.
Publicado: (2014)

Safety of Tacrolimus Monotherapy within 12 Months after Liver Transplantation in the Era of Reduced Tacrolimus and Mycophenolate Mofetil: National Registry Study
por: Kim, Deok Gie, et al.
Publicado: (2022)

Alternative Living Kidney Donation Programs Boost Genetically Unrelated Donation
por: Poldervaart, Rosalie A., et al.
Publicado: (2015)

Immunological Monitoring of Renal Transplant Recipients to Predict Acute Allograft Rejection Following the Discontinuation of Tacrolimus
por: Kreijveld, Ellen, et al.
Publicado: (2008)

Living Donor Kidney Transplant in Recipients With Glomerulonephritis: Donor Recipient Biologic Relationship and Allograft Outcomes
por: El-Rifai, Rasha, et al.
Publicado: (2023)

Tacrolimus monotherapy in a patient with lupus flare using once-daily administration protocol
por: Tanaka, Hiroshi, et al.
Publicado: (2011)

Effectiveness and safety of topical tacrolimus monotherapy for repigmentation in vitiligo: a comprehensive literature review
por: Sisti, Andrea, et al.
Publicado: (2016)

Switching Stable Kidney Transplant Recipients to a Generic Tacrolimus Is Feasible and Safe, but It Must Be Monitored
por: González, Fernando, et al.
Publicado: (2017)

A Low Fixed Tacrolimus Starting Dose Is Effective and Safe in Chinese Renal Transplantation Recipients
por: Tang, Jiang-Tao, et al.
Publicado: (2018)

High Tacrolimus Intrapatient Variability and Subtherapeutic Immunosuppression are Associated With Adverse Kidney Transplant Outcomes
por: Mendoza Rojas, Aleixandra, et al.
Publicado: (2022)

Soluble Urokinase Receptor and Mortality in Kidney Transplant Recipients
por: Morath, Christian, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_t071q4egri0pc437bmc7bbrgof